SignatureFD’s Relay Therapeutics RLAY Stock Holding History

SignatureFD’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$48.2K	Hold	2,668	–	–	﹤0.01%	1979
2026 Q2	$49.9K	Sell	2,668 -456	-15%	-$6.62K	﹤0.01%	1890
2026 Q1	$31.1K	Hold	3,124	–	–	﹤0.01%	1990
2025 Q4	$26.4K	Hold	3,124	–	–	﹤0.01%	1983
2025 Q3	$16.3K	Hold	3,124	–	–	﹤0.01%	2206
2025 Q2	$10.8K	Buy	3,124 +1,996	+177%	+$5.94K	﹤0.01%	2322
2025 Q1	$2.96K	Buy	1,128 +968	+605%	+$3.79K	﹤0.01%	2768
2024 Q4	$659	Buy	+160	New	+$871	﹤0.01%	3104
2024 Q3	–	Sell	-624	Closed	-$4.07K	–	3303
2024 Q2	$4.07K	Buy	+624	New	+$4.26K	﹤0.01%	2578
2023 Q3	–	Sell	-75	Closed	-$942	–	3287
2023 Q2	$942	Sell	75 -463	-86%	-$5.76K	﹤0.01%	2985
2023 Q1	$8.86K	Buy	+538	New	+$9.6K	﹤0.01%	2271
2022 Q2	–	Sell	-51	Closed	-$2K	–	3307
2022 Q1	$2K	Buy	+51	New	+$1.24K	﹤0.01%	2844
2021 Q4	–	Sell	-495	Closed	-$16K	–	3242
2021 Q3	$16K	Buy	+495	New	+$16.7K	﹤0.01%	1863

Other funds holding RLAY

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

SignatureFD's RLAY Position: Q3 2026 in Review

SignatureFD held its Relay Therapeutics (RLAY) position steady in Q3 2026 at 2,668 shares worth $48.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1979.

SignatureFD first reported a position in RLAY in Q3 2021 and has held it in 13 quarters since. The position peaked at $49.9K in Q2 2026. 95 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.

SignatureFD held 2,668 shares of Relay Therapeutics worth $48.2K as of Q3 2026.
SignatureFD left its Relay Therapeutics share count unchanged in Q3 2026.
Relay Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #1979 holding.
SignatureFD first reported a position in Relay Therapeutics in Q3 2021 and has held it in 13 quarters since.
SignatureFD's Relay Therapeutics position peaked at $49.9K in Q2 2026.
95 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.